Strikingly, genetic restriction of IL11 signaling by either ablation of the IL11Rα co‐receptor subunit, or therapeutic administration of the antagonistic “IL11‐Mutein” variant, limits the growth of tumors driven by excessive signaling of the canonical WNT pathway resulting from oncogenic β‐catenin/CTBNN1 or APC mutations that underpin 80% of human colon cancer (Putoczki et al, 2013). This evidence concerns the gene IL11 and malignant colon neoplasm.